EUVIMEDEUVIMED entdecken
Crossref

Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer

Kazuaki Matsui, Yutaka Miyawaki iD, Yusuke Suzuki, Tasuku Furube, Masatoshi Yoshizawa, Tetsuro Toriumi, Gen Ebara, Hiroshi Sato, Shinichi Sakuramoto

Diseases of the Esophagus · 02.03.2026 · 39 (2)

DOI: 10.1093/dote/doag036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, online erschienen am 19.04.2026. Verfasst von Kazuaki Matsui und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan. Hauptthemen laut MEDLINE: Esophageal Neoplasms, Immune Checkpoint Inhibitors, Neoplasm Recurrence, Local. Die Arbeit nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Predictors of treatment outcomes for immune checkpoint inhibitors (ICIs) remain controversial. This study investigated the association between the occurrence of immune-related adverse events (irAEs) and treatment outcomes in patients with unresectable advanced or recurrent esophageal cancer (EC) receiving ICI combination regimens. This single-center retrospective study evaluated patients with unresectable or recurrent esophageal cancer treated with ICI combination regimens, including ICI + chemotherapy or ICI + ICI. Patients were categorized into irAE (+) and irAE (−) groups. Clinical outcomes, including progression-free survival (PFS), overall survival (OS), and complete response (CR)/partial response (PR) rate, were compared between the two groups. Survival curves were estimated using the Kaplan–Meier method and compared via log-rank tests, and independent prognostic factors were identified using multivariate Cox proportional hazards models. A total of 100 patients were included, consisting of 28 (28.0%) in the irAE (+) group and 72 (72.0%) in the irAE (−) group. The study cohort comprised 82 males and 18 females (median age: 70 years). Fifty-three patients had unresectable EC, whereas 47 had recurrent EC. Eighty-three patients received an ICI + chemotherapy regimen, and 17 received an ICI + ICI regimen. The irAE (+) group showed significantly better PFS and OS compared with the irAE (−) group (P < 0.001 and P = 0.020, respectively). Significantly improved survival outcomes in the irAE (+) group were also observed in PFS of ICI + chemotherapy and in both PFS and OS of ICI + ICI. In multivariate analysis, performance status ≥2 and occurrence of irAE were identified as independently associated factors for shorter and longer PFS, respectively (P = 0.012 and 0.003). Although the irAE (+) group showed a numerically higher CR/PR rate than the irAE (−) group, no statistically significant difference was observed. IrAE occurrence was identified as an independent factor associated with improved PFS in patients with unresectable or recurrent EC who were treated with ICI combination regimens. They may serve as useful predictors for identifying patients likely to benefit from ICI treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Esophageal NeoplasmsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalHumansFemaleMaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeProgression-Free SurvivalAged, 80 and overKaplan-Meier EstimatePrognosisProportional Hazards ModelsAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

chronic diseaseesophageal neoplasmsimmune checkpoint inhibitorsimmunotherapyprognosis

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Gastroenterological Surgery, Saitama Medical University International Medical Center, Saitama, Japan.

ORCID-Profile: Yutaka Miyawaki

Zitieren

APA

Matsui, K., Miyawaki, Y., Suzuki, Y., Furube, T., Yoshizawa, M., Toriumi, T., Ebara, G., Sato, H., & Sakuramoto, S. (2026). Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer. Diseases of the Esophagus, 39(2). https://doi.org/10.1093/dote/doag036

Vancouver

Matsui K, Miyawaki Y, Suzuki Y, Furube T, Yoshizawa M, Toriumi T, et al. Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer. Diseases of the Esophagus. 2026;39(2). doi:10.1093/dote/doag036

BibTeX
@article{Matsui2026,
  author = {Matsui, Kazuaki and Miyawaki, Yutaka and Suzuki, Yusuke and Furube, Tasuku and Yoshizawa, Masatoshi and Toriumi, Tetsuro and Ebara, Gen and Sato, Hiroshi and Sakuramoto, Shinichi},
  title = {Relationship between immune-related adverse events and long-term survival in patients treated with immune checkpoint inhibitors for unresectable advanced or recurrent esophageal cancer},
  journal = {Diseases of the Esophagus},
  year = {2026},
  volume = {39},
  number = {2},
  doi = {10.1093/dote/doag036}
}
Kostenlos starten →